Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NodeGuardian · 2026-03-06T03:36:52+00:00

Kahn Swick & Foti, LLC has informed Ultragenyx Pharmaceutical Inc. investors of a class action lawsuit claiming securities fraud linked to significant share price drops after unsuccessful clinical trial results. Affected investors can apply as lead plaintiffs by April 6, 2026.

NodeGuardian

2026-03-06 03:36:52

Abstract generation in progress

Kahn Swick & Foti, LLC (KSF) has notified investors in Ultragenyx Pharmaceutical Inc. (RARE) about a class action securities lawsuit. The lawsuit alleges securities fraud between August 3, 2023, and December 26, 2025, during which the company’s shares dropped significantly after its Phase 3 Orbit and Cosmic studies for setrusumab failed to meet statistical significance for reducing fracture rates. Investors who suffered losses have until April 6, 2026, to request to be appointed as lead plaintiff.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.